1IONS Stock Overview

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. More details

1IONS fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 67.5% below our estimate of its fair value

Revenue is forecast to grow 23.48% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Ionis Pharmaceuticals, Inc. Competitors

Philogen

BIT:PHIL

€910.5m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.6b

Arterra Bioscience

BIT:ARBS

€14.9m

Chongqing Zhifei Biological Products

SZSE:300122

CN¥46.6b

Price History & Performance

Summary of share price highs, lows and changes for Ionis Pharmaceuticals
Historical stock prices
Current Share Price	US$29.77
52 Week High	US$0
52 Week Low	US$0
Beta	0.15
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	15.16%

Recent updates

Shareholder Returns

	1IONS	IT Biotechs	IT Market
7D	2.6%	1.6%	2.9%
1Y	n/a	0.3%	14.1%

Return vs Industry: Insufficient data to determine how 1IONS performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1IONS performed against the Italian Market.

Price Volatility

Is 1IONS's price volatile compared to industry and market?
1IONS volatility
1IONS Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1IONS's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1IONS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1989	1,069	Brett Monia	www.ionis.com

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.

Ionis Pharmaceuticals, Inc. Fundamentals Summary

How do Ionis Pharmaceuticals's earnings and revenue compare to its market cap?
1IONS fundamental statistics
Market cap	€4.79b
Earnings (TTM)	-€410.81m
Revenue (TTM)	€643.30m

7.4x

P/S Ratio

-11.7x

P/E Ratio

Is 1IONS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1IONS income statement (TTM)
Revenue	US$717.25m
Cost of Revenue	US$898.40m
Gross Profit	-US$181.15m
Other Expenses	US$276.88m
Earnings	-US$458.03m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-2.88
Gross Margin	-25.26%
Net Profit Margin	-63.86%
Debt/Equity Ratio	380.3%

How did 1IONS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 09:46
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 45 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ishan Majumdar	Baptista Research
James Birchenough	Barclays
Huidong Wang	Barclays

Ionis Pharmaceuticals BIT:1IONS Stock Report